Glutamate Dehydrogenase Applicability in Clinical Practice

Article Sidebar

PDF Download
Published Mar 21, 2021
DOI: https://doi.org/10.18103/mra.v9i3.2350

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Matej Kravos, M.D.,Ph.D.
ZPA dr. Kravos, Trg svobode 26, SI-2310 Slovenska Bistrica, Slovenia

Abstract

Glutamate dehydrogenase (GLDH) catalyzes reversible deamination of glutamate into alpha-ketoglutarate and ammonium ion. In the metabolism of a cell, GLDH has the key role of acting as an interface between carbohydrates and amino acids in the vicinity of the citric acid cycle and urea cycle. In the brain, GLDH appears in astrocytic processes associated with glutamatergic terminals, but it is also involved in glia metabolic processes. GLDH probably protects postsynaptic membranes against the neuroexcitotoxic glutamate effect.


GLDH is an equally accurate marker of alcoholism in comparison to others, if its significantly faster decrease is taken into consideration. Watching changes in the activity of laboratory markers of alcoholism, after cessation of drinking, is an effective yet overlooked aid in diagnostics.


The fast increase of leukocytes GLDH activity is specific for alcohol addiction. Alcohol consumption reduces GLDH activity to some extent and consecutively it could lead to increased protein production and strengthen of diminished leukocyte protective ability.


The gradual decrease in GLDH activity may be one of key factors for neurodegenerative ageing processes. The decrease in GLDH activity in the cerebrospinal fluid of patients with neurodegenerative disorders may be one of the reasons for the neuroexcitotoxic glutamate effect.


The probable decrease in GLDH activity in the cerebrospinal fluid of patients with neurodegenerative disorders and of patients with nerve, nerve root and plexus disorders needs further investigations to be adequately understood.

Keywords: glutamate dehydrogenase, isoform, leukocyte, alcohol, addiction, , neurodegeneration, ageing, decision trees, diagnostics, cerebrospinal fluid

Article Details

How to Cite
KRAVOS, Matej. Glutamate Dehydrogenase Applicability in Clinical Practice. Medical Research Archives, [S.l.], v. 9, n. 3, mar. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2350>. Date accessed: 23 nov. 2024. doi: https://doi.org/10.18103/mra.v9i3.2350.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 9 No 3 (2021): Vol.9 Issue 3 March 2021
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Thomas L. Glutamat-dehydrogenase. In: Thomas L, ed. Labor und Diagnose. 6.Aufl. Frankfurt/Main: TH – Books Verlagsgesellschaft Gmbh; 2005:103-106.
2. Devlin, Thomas M. Textbook of biochemistry with clinical correlations. New York: Wiley & Sons; c2001:784-785, 895-896.
3. Lee WK, Shin S, Cho SS, Park JS. Purification and characterization of glutamate dehydrogenase as another isoprotein binding to the membrane of rough endoplasmatic reticulum. J Cell Biochem. 1999;76:244-253.
4. Schmidt ES, Schmidt FW. Glutamate dehydrogenase: Biochemical and clinical aspects of an interesting enzyme. Clin Chim Acta. 1988;43:43-56.
5. Kravos M, Kralj G, Malešič I. Encimi v likvorju. Slovene Medical Soc. 2008;77:593–599.
6. Plaitakis A, Zaganas I. Regulation of human glutamate dehydrogenases: Implications for glutamate, ammonia and energy metabolism in brain. J Neurosci Res. 2001;66(5): 899-908.
7. Stahl, Stephen. Psychosis and schizophrenia. Cambridge, IN: Essential psychopharmacology; c2000:365-399.
8. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration amyotrophic lateral sclerosis: A hypothesis. Ann Neurol. 1990;28(1):3-8.
9. Gelder M, Mayou R, Geddes J. Problems due to use of alcohol and other psychoactive substances. In: Gelder M, Mayou R, Geddes J, eds. Psychiatry. 2nd ed. Oxford, UK: Oxford University Press; 1999:259-287.
10. Ropero-Miller JD, Winecker RE. Alcoholism. In: Kaplan LA, Pesce AJ, Kazimierczak SC, eds. Clinical chemistry theory, analysis, correlations. 4th ed. St. Louis, MO: Mosby; 2003:639-656.
11. Kravos M, Malešič I. Carbohydrate deficient transferrin (CDT) as a marker of alcohol dependency. Slovene Medical Soc. 2008;77:189–198.
12. Bais R, Panteghini M. Priciples of clinical enzymology. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. St.Louis, MO: Elsevier Saunders; 2006:191-218.
13. Kravos M, Malešič I. Kinetics and Isoforms of Serum Glutamate Dehydrogenase in Alcoholics. Alcohol Alcohol. 2008;43(3):281-286.
14. Anton RF, Stout RL, Roberts JS, Allen JP. The effect of drinking intensity and frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res. 1998;22:1456-1462.
15. Arndt T. Carbohydrate-deficient Transferrin (Kohlehydrat-defizient Transferrin) - CDT. In: Thomas L, ed. Labor und Diagnose. 6.Aufl. Frankfurt/Main: TH – Books Verlagsgesellschaft Gmbh; 2005:945-953.
16. Kravos M, Malešič I. Changes in leukocyte glutamate dehydrogenase activity in alcoholics upon break in alcohol consumption. Clin Biochem. 2010;43(3):272–277.
17. Kravos M, Malešič I. The hospital treatment of alcoholics in eastern Slovenia. Slovene Medical Soc. 2011;80(4):258-267.
18. Bisaga A, Laposata M, Xie S, Evans SM. Comparison of serum fatty acid ethyl esters and urinary 5-hydroxytryptophol as biochemical markers of recent ethanol consumption. Alcohol Alcohol. 2005;40(3):214-218.
19. Dinevski D, Povalej P, Kravos M. Intelligent data analysis for the diagnosis of alcohol dependence syndrome. J Int Med Res. 2011;39(3):988-1000.
20. Plaitakis A, Berl S. Oral glutamate loading in disorders with spinocerebellar and extrapyramidal involvement: Effect on plasma glutamate, aspartate and taurine. J Neural Transm. 1983; 19,Suppl: 65-74.
21. Kravos M, Malešič I. Glutamate dehydrogenase activity in leukocytes and ageing. Neurodegenerative Dis. 2010;7(4):239–242.
22. Iwatsuji K, Nakamura S, Kameyama M. Lymphocyte glutamate dehydrogenase activity in normal aging and neurological diseases. Gerontology 1989;35:218–24.
23. Kravos M, Malešič I. The Role of Glutamate Dehydrogenase Activity in Development of Neurodegenerative Disorders. World Journal of Neuroscience. 2017; 7:181-192.